BioSpace News Archive

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment of its phase 2 CALLIPER trial of lead asset, vidofludimus calcium, in patients with progressive multiple sclerosis.

Eagle Pharmaceuticals, Inc. reiterated its previously issued guidance for the 2023 fiscal year.

Tonix Pharmaceuticals Holding Corp. announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m. ET.

Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2023.

BlueWind Medical, Ltd. today announced that the US Food and Drug Administration (FDA) granted a De Novo marketing request for the Revi System, a transformative tibial neuromodulation therapy for the treatment of the symptoms of urgency incontinence alone or in combination with urinary urgency.

CareDx, Inc. today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas.

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to purchase an aggregate of 110,000 shares to Gaetano Bonifacio, M.D., the Company’s new Vice President, Global Medical Affairs.

Johnson & Johnson’s subsidiary Janssen made headlines again in August 2023 when the FDA approved its product talquetamab under the agency’s accelerated approval program.

Altruix announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).

Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief Sustainability Officer effective immediately.